- Home
- HST vs EXAS Comparison
HST vs EXAS Comparison
Compare HST & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HST
- EXAS
- Stock Information
- Founded
- HST 1927
- EXAS 1995
- Country
- HST United States
- EXAS United States
- Employees
- HST N/A
- EXAS N/A
- Industry
- HST Real Estate Investment Trusts
- EXAS Medical Specialities
- Sector
- HST Real Estate
- EXAS Health Care
- Exchange
- HST Nasdaq
- EXAS Nasdaq
- Market Cap
- HST 10.0B
- EXAS 8.6B
- IPO Year
- HST N/A
- EXAS N/A
- Fundamental
- Price
- HST $16.91
- EXAS $47.47
- Analyst Decision
- HST Buy
- EXAS Strong Buy
- Analyst Count
- HST 12
- EXAS 22
- Target Price
- HST $17.71
- EXAS $66.43
- AVG Volume (30 Days)
- HST 11.2M
- EXAS 4.0M
- Earning Date
- HST 07-30-2025
- EXAS 08-06-2025
- Dividend Yield
- HST 5.57%
- EXAS N/A
- EPS Growth
- HST N/A
- EXAS N/A
- EPS
- HST 0.94
- EXAS N/A
- Revenue
- HST $5,938,000,000.00
- EXAS $2,939,949,000.00
- Revenue This Year
- HST $6.04
- EXAS $14.61
- Revenue Next Year
- HST $1.74
- EXAS $12.71
- P/E Ratio
- HST $18.04
- EXAS N/A
- Revenue Growth
- HST 8.38
- EXAS 12.55
- 52 Week Low
- HST $12.22
- EXAS $38.81
- 52 Week High
- HST $19.37
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- HST 67.19
- EXAS 52.00
- Support Level
- HST $15.65
- EXAS $44.90
- Resistance Level
- HST $16.09
- EXAS $46.26
- Average True Range (ATR)
- HST 0.34
- EXAS 1.88
- MACD
- HST 0.11
- EXAS 0.61
- Stochastic Oscillator
- HST 98.90
- EXAS 94.03
About HST Host Hotels & Resorts Inc.
Host Hotels & Resorts owns 81 predominantly urban and resort upper-upscale and luxury hotel properties representing over 43,000 rooms, mainly in the United States. Host recently sold off the company's interests in a joint venture owning a portfolio of hotels throughout Europe and also sold other joint ventures that owned properties in Asia and the United States. The majority of Host's portfolio operates under the Marriott and Starwood brands.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.